Echo Therapeutics
- Company typePublic
- Founded1989
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Echo Therapeutics does
Echo Therapeutics (OTCMKTS: ECTE) is a Philadelphia-based, publicly traded medical device company developing the Symphony tCGM System, a non-invasive (needle-free) continuous glucose monitor targeting insulin-dependent diabetes patients. The platform is positioned as an alternative to incumbent needle-based CGM devices and serves a global diabetes population stated at over 537 million adults. The company's core technology rests on continuous glucose monitoring sensor capability, consolidated historically through the 2007 acquisition of Sontra Medical. No pricing model, distribution channels, marketing channels, named customers, or commercial revenue are disclosed in the available data, indicating a pre-commercial or very early commercial stage.
The company has funded operations through a series of equity and debt-style financings totaling approximately $44.7 million across at least ten disclosed rounds between 2009 and 2016, with named institutional participation from Platinum-Montaur Life Sciences, Medical Technologies Innovation Asia, and Platinum Partners. Round sizes peaked in 2013 at $12.5M and $10M and have since declined to $4M (2014) and $1.8M (2016), suggesting tightening access to capital. The leadership team is small and includes a Founder/CEO (Patrick Mooney), a President/CEO (Scott W. Hollander), a combined CEO/CFO (Alan Schoenbart), a VP of Marketing & Commercial Development (David Walton), and a VP of Manufacturing & Global Supply Chain (Dan Sunday), consistent with a clinical-stage device company preparing for commercial manufacturing and launch. No FDA approvals, clinical milestones, partnerships, patents, or commercial agreements are documented in the source data, and the financial figures provided contain implausibly large values that appear to be data errors, leaving a significant gap in verified operating performance.
Echo Therapeutics firmographics
Firmographics- Name
- Echo Therapeutics
- Website
- https://echotx.com
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Echo Therapeutics industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
Keywords
Where Echo Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Markets served
Echo Therapeutics business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Echo Therapeutics product offering
Product offeringCore offering
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) continuous glucose monitoring system intended for diabetes patients. The system delivers continuous glucose visibility and automated alerts to help insulin-dependent patients manage blood glucose levels more effectively.
Differentiator
Problem solved
Functional benefit
Products and services
- Symphony tCGM System A novel, non-invasive (needle-free) continuous glucose monitoring system designed for diabetes patients, particularly insulin-dependent individuals. The system provides continuous glucose visibility and automated alerts to support blood glucose management.
Companies that use Echo Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Echo Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Echo Therapeutics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Echo Therapeutics competitors and assessment
Company assessmentDirect peers
- Dexcom: Dexcom is the leading dedicated CGM manufacturer worldwide with ~24% market share. It sells factory-calibrated CGM systems with smartphone connectivity and integrated insulin pump compatibility - directly competing with Echo's planned needle-free tCGM within the same diabetes patient population.
- Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the highest-volume CGM franchise on the market (~28% share, multiple millions of users) and the dominant needle-free applicator incumbent. Echo's Symphony positions against FreeStyle Libre on disposability, wear-time, and skin prep - making Abbott the closest direct CGM competitor.
- Nova Biomedical: Nova Biomedical manufactures StatStrip glucose and ketone hospital meters and is developing an in-hospital CGM. Comparable in size and stage to Echo, it competes on glucose monitoring accuracy and clinical use cases relevant to Echo's diabetes patient segment.
- Senseonics (Eversense): Senseonics produces Eversense, the only long-term implantable CGM in the market. Comparable in size and stage to Echo, it competes on CGM form-factor differentiation and long wear time - making it a relevant emerging peer in the same CGM device category with adjacent differentiating angles.
- Medtronic Diabetes: Medtronic produces the Guardian CGM and partners with insulin delivery devices (780G), targeting the same insulin-dependent patient population as Echo. While Medtronic is broader, its diabetes division is a direct CGM competitor with integrated closed-loop capability that Echo's tCGM would need to interoperate with.
Emerging players
- GlySens: GlySens is a private company developing a fully implanted long-term CGM sensor (Eclipse). As an early-stage player in needle-free / implant-based glucose sensing, it competes on similar CGM form-factor differentiation in the same diabetes technology category.
- Tandem Diabetes Care: Tandem manufactures the t:slim X2 insulin pump with Control-IQ closed-loop algorithm that uses CGM input data. While Tandem does not directly make CGM, it is an emerging competitor at the integrated pump+CGM decision support layer that Echo's tCGM data would integrate with.
- Insulet (Omnipod): Insulet manufactures Omnipod tubeless insulin pumps that integrate directly with CGM data (Abbott and Dexcom). While not a direct CGM maker, Insulet competes to be the closed-loop partner in the same insulin-dependent patient workflow that Echo's tCGM would feed into.
Broad incumbents
- Roche Diabetes Care: Roche operates the Accu-Chek brand of blood glucose meters and is an established incumbent in glucose monitoring. Although Roche exited pure CGM, it remains relevant as a broad incumbent player serving the same diabetes patient base with adjacent monitoring solutions.
- LifeScan (Johnson & Johnson): LifeScan, historically owned by J&J and now a standalone venture, has been the long-standing leader in blood glucose monitoring (OneTouch) and competes in the same diabetes self-monitoring category. It represents a broad incumbent alternative for the diabetes patient population Echo is targeting.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Echo Therapeutics social profiles
Digital presenceEcho Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Echo Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Echo Therapeutics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Echo Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Echo Therapeutics
What does Echo Therapeutics do?
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) continuous glucose monitoring system intended for diabetes patients. The system delivers continuous glucose visibility and automated alerts to help insulin-dependent patients manage blood glucose levels more effectively.
Is Echo Therapeutics a public or private company?
Echo Therapeutics is a public company. It is classified as public and is currently operating.
When was Echo Therapeutics founded?
Echo Therapeutics was founded in 1989. It employs 11 to 50 people.
Where is Echo Therapeutics based?
Echo Therapeutics is headquartered in Philadelphia, United States, in the North America region.
Who are Echo Therapeutics's main competitors?
Direct peers on record are Dexcom, Abbott Diabetes Care (FreeStyle Libre), Nova Biomedical, Senseonics (Eversense) and Medtronic Diabetes. Emerging players are GlySens, Tandem Diabetes Care and Insulet (Omnipod). Broad incumbents are Roche Diabetes Care and LifeScan (Johnson & Johnson).
Does Echo Therapeutics have an API?
No public API is recorded for Echo Therapeutics.
What industry is Echo Therapeutics in?
Echo Therapeutics's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems. Its NAICS code is 334510 and its SIC code is 3841.